Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verteporfin PDT + Ranibizumab vs Ranibizumab Monotherapy in AMD
NCT00433017Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2007
- Primary completion
- Jul 2009
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 12
01
Overview
A Phase 3 trial of verteporfin in age-related macular degeneration (AMD), choroidal neovascularization (CNV), sponsored by Novartis. Started May 2007; status: terminated.
02
Drugs
verteporfin
03
Conditions
age-related macular degeneration (AMD)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT00433017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433017.